EpiCast Report: Head and Neck Cancers – Epidemiology Forecast to 2024

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995
Buy Report View Sample

Published: February 01, 2016 Report Code: GDHCER115-16-ST

Select Item

Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid. HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck — more than 80% of all HNCs are squamous cell carcinomas. HNCs are common in several regions across the globe and account for 600,000 new cases annually worldwide.GlobalData epidemiologists forecast an increase in diagnosed incident cases of HNCs in the 7MM from 151,393 diagnosed incident cases in 2014 to 174,056 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 1.50% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of HNCs in the 7MM, with 65,663 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of HNCs, with 12,702 diagnosed incident cases in 2024. The diagnosed incident cases of thyroid cancer in the 7MM are expected to increase from 93,225 diagnosed incident cases in 2014 to 123,504 diagnosed incident cases in 2024, with an AGR of 3.25% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of thyroid cancer in the 7MM with 81,286 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of thyroid cancer with 3,233 diagnosed incident cases in 2024.

Scope

The Head and neck cancers (HNCs) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of HNCs segmented into three sub-groups: cancers of the lip, oral cavity, and pharynx; cancers of the nose, sinuses, and related structures; and cancers of the larynx, in these markets. It also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HNCs (excluding nose, sinuses, and related cancers). Additionally, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of thyroid cancer in the 7MM. The diagnosed incident cases of HNCs (excluding nose, sinuses, and related cancers) and thyroid cancer are segmented by age, sex, clinical stage at diagnosis, and histology.

The HNCs epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Reports

3Epidemiology

3.1Disease Background

3.2Risk Factors and Comorbidities

3.3Global Trends

3.3.1Incidence

3.3.2Relative Survival – 7MM

3.4Forecast Methodology

3.4.1Sources Used

3.4.2Sources Not Used

3.4.3Forecast Assumptions and Methods

3.5Epidemiological Forecast for HNCs and Thyroid Cancer (2014–2024)

3.5.1Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer

3.5.2Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers

3.5.3Diagnosed Incident Cases of Larynx Cancer

3.5.4Diagnosed Incident Cases of HNCs

3.5.5Diagnosed Incident Cases of Thyroid Cancer

3.5.6Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer

3.5.7Age-Specific Diagnosed Incident Cases of Larynx Cancer

3.5.8Age-Specific Diagnosed Incident Cases of Thyroid Cancer

3.5.9Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer

3.5.10Sex-Specific Diagnosed Incident Cases of Larynx Cancer

3.5.11Sex-Specific Diagnosed Incident Cases of Thyroid Cancer

3.5.12Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer

3.5.13Age-Standardized Diagnosed Incidence of Larynx Cancer

3.5.14Age-Standardized Diagnosed Incidence of Thyroid Cancer

3.5.15Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis

3.5.16Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis

3.5.17Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis

3.5.18Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution

3.5.19Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution

3.5.20Diagnosed Incident Cases of Larynx Cancer by Histology Distribution

3.5.21Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution

3.5.22Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer

3.5.23Five-Year Diagnosed Prevalent Cases of Larynx Cancer

3.5.24Five-Year Diagnosed Prevalent Cases of Thyroid Cancer

3.6Discussion

3.6.1Epidemiological Forecast Insight

3.6.2Limitations of the Analysis

3.6.3Strengths of the Analysis

4Appendix

4.1Bibliography

4.2About the Authors

4.2.1Epidemiologists

4.2.2Reviewers

4.2.3Global Director of Therapy Analysis and Epidemiology

4.2.4Global Head of Healthcare

4.3About GlobalData

4.4About EpiCast

4.5Disclaimer

Table

Table 1: HNCs Clinical Stages at Diagnosis

Table 2: Risk Factors for HNCs

Table 3: Trends in the Age-Adjusted Incidence of Lip, Oral Cavity, and Pharynx Cancer in the 7MM, All Ages, 1998–2007

Table 4: Trends in the Age-Adjusted Incidence of Larynx Cancer in the 7MM, All Ages, 1998–2007

Table 5: Trends in the Age-Adjusted Incidence of Thyroid Cancer in the 7MM, All Ages, 1998–2007

Table 6: Trends in the Five-Year Relative Survival (%) of HNCs and Thyroid Cancer in the 7MM, Both Sexes, 1993–2007

Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer

Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Larynx Cancer

Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer

Table 10: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Thyroid Cancer

Table 11: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer

Table 12: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Larynx Cancer

Table 13: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Thyroid Cancer

Table 14: 7MM, Sources of Epidemiological Data Used for the Segmentation of Diagnosed Incident Cases of HNCs (Excluding Nose, Sinuses, and Related Cancers) and Thyroid Cancer by Clinical Stage at Diagnosis

Table 15: 7MM, Sources of Epidemiological Data Used for the Segmentation of the Diagnosed Incident Cases HNCs and Thyroid Cancer by Histology Distribution

Table 16: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014–2024

Table 17: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014–2024

Table 18: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014–2024

Table 19: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014–2024

Table 20: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014–2024

Table 21: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N (Row %), 2014

Table 22: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N (Row %), 2014

Table 23: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N (Row %), 2014

Table 24: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N (Row %), 2014

Table 25: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N (Row %), 2014

Table 26: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N (Row %), 2014

Table 27: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014–2024

Table 28: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014–2024

Table 29: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014–2024

Figures

Figure 1: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014–2024

Figure 2: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014–2024

Figure 3: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014–2024

Figure 4: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014–2024

Figure 5: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014–2024

Figure 6: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N, 2014

Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N, 2014

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N, 2014

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N, 2014

Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N, 2014

Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N, 2014

Figure 12: 7MM, Age-Standardized Diagnosed Incidence Cases of Lip, Oral Cavity, and Pharynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014

Figure 13: 7MM, Age-Standardized Diagnosed Incidence Cases of Larynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014

Figure 14: 7MM, Age-Standardized Diagnosed Incidence Cases of Thyroid Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014

Figure 15: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014

Figure 16: 7MM, Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014

Figure 17: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014

Figure 18: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 19: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 20: 7MM, Diagnosed Incident Cases of Larynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 21: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 22: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014–2024

Figure 23: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014–2024

Figure 24: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014–2024

Frequently asked questions

EpiCast Report: Head and Neck Cancers – Epidemiology Forecast to 2024 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

Most Popular
$7,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Head and Neck Cancers – Epidemiology Forecast to 2024 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Head and Neck Cancers – Epidemiology Forecast to 2024 in real time.

  • Access a live EpiCast Report: Head and Neck Cancers – Epidemiology Forecast to 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more